Abstract
Pleural exudative lymphocytes (PLEL) from a 60-year-old female patient showed high cytotoxicity against the autologous mammary tumor line, HMC-2, and NK-susceptible K562 cells, although PLEL demonstrated only weak cytotoxic potentials against several allogeneic tumor lines. We successfully obtained seven cytotoxic T cell clones from PLEL bulk populations, and assessed the possibility that these lymphocytes are simply natural killer (NK)-like cells or have the dual cytotoxic activity of cytotoxic T lymphocytes (CTL) and NK-like cells. These clones, designated as TcHMC-2, showed strong cytotoxicity against both HMC-2 and K562 cells. In contrast, allogeneic human peripheral blood-derived NK cells could not kill HMC-2 targets. Furthermore, a blocking study of TcHMC-2 cytotoxicity using monoclonal antibodies against CD3, CD8 and human MHC class I products showed that all of these antigen molecules were involved in the cytotoxicity of TcHMC-2 clone against autologous HMC-2 cells, indicating MHC class I recognitive cytotoxicity. These data indicate that the TcHMC-2 clone may have dual cytotoxicity with CTL- and NK-like activity against autologous HMC-2 mammary tumor and K562 cells, respectively.
References
Sep 1, 1978·British Journal of Cancer·B M VoseE Klein
Sep 10, 1976·Science·D A MorganR Gallo
Jan 1, 1979·Journal of Immunological Methods·C GutierrezM Kreisler
May 15, 1975·International Journal of Cancer. Journal International Du Cancer·M LieberG Todaro
Oct 1, 1988·Immunology Today·T Hercend, R E Schmidt
Oct 16, 1986·Nature·P MoingeonC Bohuon
Jan 1, 1986·Annual Review of Immunology·R B HerbermanJ R Ortaldo
Jun 19, 1986·Nature·W S TrimbleJ C Roder
Jun 1, 1982·The Journal of Experimental Medicine·E A GrimmS A Rosenberg
Jul 1, 1984·The Journal of Experimental Medicine·H YsselJ E de Vries
Mar 1, 1984·The Journal of Experimental Medicine·A MorettaJ C Cerottini
Mar 15, 1981·International Journal of Cancer. Journal International Du Cancer·F VánkyE Klein
Jan 15, 1982·International Journal of Cancer. Journal International Du Cancer·B M Vose, G D Bonnard
Jan 13, 1983·Nature·T HercendJ Ritz
Citations
Oct 1, 1995·Cancer Immunology, Immunotherapy : CII·J HaldM H Claesson
Oct 2, 1992·Journal of Immunological Methods·Y WadaK Kikuchi
May 7, 1999·International Journal of Immunopharmacology·J W Hadden
Jun 30, 2000·Cellular Immunology·T FujitaN Sato
Jan 1, 1991·Cancer Immunology, Immunotherapy : CII·G PawelecF W Busch
Jan 1, 1993·Biotherapy·F OkanoH Murakami
Dec 17, 2009·Journal of Translational Medicine·Ichiya HonmaNoriyuki Sato
Mar 15, 1995·Cancer·T YasoshimaK Kikuchi
Feb 1, 1997·Japanese Journal of Cancer Research : Gann·A MiyazakiK Kikuchi
Aug 1, 1993·Japanese Journal of Cancer Research : Gann·Y WadaK Kikuchi
Feb 28, 2001·Microbiology and Immunology·K KankiN Sato
Nov 1, 1994·Cancer Immunology, Immunotherapy : CII·S Q LiuT Ohno
Dec 3, 2005·Cancer Research·Hiroko AsanumaNoriyuki Sato